Fab Platform

Selecting a Fab instead of a full-length antibody as a drug product may be driven by the need to make improvements in the product’s biology, or by intellectual property constraints and development timelines. The BaroFold Fab system offers significant manufacturing cost advantages over other methods of Fab production and in certain cases, enable the continued development of the protein when other refolding technologies cannot provide high levels of properly folded, active material.

BaroFold’s PreEMT technology effectively refolds Fabs from inclusion bodies produced from E. coli fermentation. The process operates at high protein concentration and provides high yields relative to chaotrope-based refolding techniques or periplasmic expression.